UG Healthcare Yönetim

Yönetim kriter kontrolleri 2/4

UG Healthcare CEO'su Jun Linn Lee, Oct2020 tarihinde atandı, in görev süresi 4.58 yıldır. şirketin hisselerinin 0.36% doğrudan sahiptir ve bu hisselerin değeri SGD 226.14K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 6 yıldır.

Anahtar bilgiler

Jun Linn Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.6yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jun Linn Lee (39 yo)

4.6yrs

Görev süresi

Mr. Jun Linn Lee has been Executive Director of UG Healthcare Corporation Limited since November 20, 2014 and its Chief Operating Officer since October 21, 2020. Mr. Lee is responsible for directing the UG...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Linn Lee	COO, Joint CEO & Executive Director	4.6yrs	Veri yok	0.36% SGD 226.1k
Jun Yih Lee	Finance Director	5.8yrs	Veri yok	0.46% SGD 290.2k
Keck Keong Lee	Executive Director	less than a year	Veri yok	Veri yok
Pek Wee Wong	Head of Manufacturing	no data	Veri yok	Veri yok
Mei Low	Company Secretary	3.9yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim: 8K7 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Linn Lee	COO, Joint CEO & Executive Director	10.5yrs	Veri yok	0.36% SGD 226.1k
Jun Yih Lee	Finance Director	10.5yrs	Veri yok	0.46% SGD 290.2k
Keck Keong Lee	Executive Director	10.5yrs	Veri yok	Veri yok
Cheong Yan Law	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Fook Choy Wong	Independent Non-Executive Chairman	less than a year	Veri yok	Veri yok
Lee Eng Ng	Independent Non-Executive Director	1.4yrs	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8K7 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/06 17:43
Gün Sonu Hisse Fiyatı	2025/05/06 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

UG Healthcare Corporation Limited 4 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Khang Chuen Ong	CGS International
John Cheong	Maybank Research Pte. Ltd.
Paul Chew	Phillip Securities Pte Ltd

UG Healthcare Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

UG Healthcare Corporation Limited Appoints Lee Jun Yih as Joint Chief Executive Officer

Ug Healthcare Corporation Limited Announces Appointment of Law Cheong Yan as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee, Effective from December 2,2024

UG Healthcare Corporation Limited, Annual General Meeting, Oct 29, 2024

Ug Healthcare Corporation Limited Announces Retirement of Mr. Wong See Keong as Executive Director, Effective 29 October 2024

UG Healthcare Corporation Limited Announces Appointment of Ng Lee Eng as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

UG Healthcare Corporation Limited Announces Cessation Vincent Leow as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

Recent updates

UG Healthcare Corporation Limited Appoints Lee Jun Yih as Joint Chief Executive Officer

First half 2025 earnings released: S$0.001 loss per share (vs S$0.008 loss in 1H 2024)

UG Healthcare Corporation Limited to Report First Half, 2025 Results on Feb 14, 2025

Ug Healthcare Corporation Limited Announces Appointment of Law Cheong Yan as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee, Effective from December 2,2024

Full year 2024 earnings released: S$0.01 loss per share (vs S$0.033 loss in FY 2023)

UG Healthcare Corporation Limited, Annual General Meeting, Oct 29, 2024

Ug Healthcare Corporation Limited Announces Retirement of Mr. Wong See Keong as Executive Director, Effective 29 October 2024

Full year 2024 earnings released: S$0.01 loss per share (vs S$0.033 loss in FY 2023)

UG Healthcare Corporation Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

UG Healthcare Corporation Limited (Catalist:8K7) completed the acquisition of 50% stake in UG NITREX, S. L. from Afaprot, S. L. and Martínez for €0.5 million.

First half 2024 earnings released: S$0.008 loss per share (vs S$0.008 loss in 1H 2023)

New major risk - Revenue and earnings growth

UG Healthcare Corporation Limited to Report First Half, 2024 Results on Feb 13, 2024

UG Healthcare Corporation Limited Announces Appointment of Ng Lee Eng as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

New minor risk - Share price stability

UG Healthcare Corporation Limited Announces Cessation Vincent Leow as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

UG Healthcare Corporation Limited, Annual General Meeting, Oct 30, 2023

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: S$0.008 loss per share (vs S$0.034 profit in 1H 2022)

UG Healthcare Corporation Limited to Report First Half, 2023 Results on Feb 14, 2023

Less than half of directors are independent

UG Healthcare Corporation Limited Approves Special Cash Dividend for the Financial Year Ended 30 June 2022, Payable on 16 December 2022

UG Healthcare Corporation Limited (Catalist:8K7) entered into a share sale agreement to acquire Indigo Teguh Sdn Bhd from Lee Keck Keong for MYR 100.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited, Annual General Meeting, Oct 28, 2022

Consensus revenue estimates fall by 12%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited Recommends Tax Exempt Special Dividend for Fiscal Year 2022

Less than half of directors are independent

Now 20% undervalued after recent price drop

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited to Report First Half, 2022 Results on Feb 11, 2022

Price target decreased to S$0.44

Full year 2021 earnings released: EPS S$0.19 (vs S$0.023 in FY 2020)

Price target decreased to S$0.55

Less than half of directors are independent

UG Healthcare Corporation Limited Provides Update on Covid-19 Situation in the Group's Manufacturing Division in Malaysia

Company Secretary Kar Yeoh has left the company

Third quarter 2021 earnings released: EPS S$0.056 (vs S$0.011 in 3Q 2020)

Price target decreased to S$0.99

Second quarter 2021 earnings released

UG Healthcare Corporation Limited to Report First Half, 2021 Results on Feb 04, 2021

New 90-day low: S$0.36

New 90-day low: S$0.23

New 90-day low: S$0.60

New 90-day low: S$0.64

First quarter 2021 earnings released: EPS S$0.039

Analysts update estimates

Annual earnings released: Revenue and earnings beat expectations

Full year earnings released - EPS S$0.023

UG Healthcare Corporation Limited has completed a Follow-on Equity Offering in the amount of SGD 19.0875 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları